Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 27Melanoma 4Sarcoma 3Liposarcoma 3Ovarian Neoplasms 2Neoplasms 2Breast Cancer Metastatic 2Thymus Neoplasms 1Teratoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neoplastic Cells, Circulating 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Mesothelioma 1Lymphoma 1Locoregional Recurrence 1Liposarcoma, Myxoid 1Lipoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1HER2-positive Advanced Breast Cancer 1HER2 Negative Breast Cancer 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Estrogen Receptor and/or Progesterone Receptor Positive 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1

Interventions

ribociclib 1pembrolizumab 1palbociclib 1epacadostat 1amrubicin 1alovudine 1Sunitinib 1Erlotinib Hydrochloride 1Drug Therapy 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thymus Neoplasms × ribociclib × Clear all
NCT02420691 2020-10-30

Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin

M.D. Anderson Cancer Center

Phase 2 Completed
21 enrolled 14 charts
Gastrointestinal

Non functioning pancreatic endocrine tumor, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡